Company intelligence / Profile preview
Scioto Biosciences, Inc.
Indianapolis, Indiana, United Statessciotobiosciences.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 1
01
Overview
Scioto Biosciences has completed a Phase Ib trial for SB-121 in patients with Autism Spectrum Disorder with positive results published in 2023. The company is also developing treatments for necrotizing enterocolitis (NEC) in premature infants.
- Therapeutic areas
- GastroenterologyPsychiatry
- Modalities
- Live Bacterial Therapeutics (LBTs)Probiotics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Genome & CompanyThe Research Institute at Nationwide Children's HospitalMonon Bioventures
Beyond the preview
Go deeper on Scioto Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scioto Biosciences, Inc..